Pharmaceutical

TerSera’s ZOLADEX LA gains Health Canada approval for breast cancer

TerSera has obtained Health Canada approval for ZOLADEX LA 10.8mg to manage oestrogen receptor-positive (ER+) early breast cancer.

May 9, 2024 - 00:00
TerSera’s ZOLADEX LA gains Health Canada approval for breast cancer
TerSera has obtained Health Canada approval for ZOLADEX LA 10.8mg to manage oestrogen receptor-positive (ER+) early breast cancer.
Read the original article

Tags:

Previous Article

BioVersys and GSK expand their partnership for TB treatment alpibectir

Next Article

Broken String Biosciences teams up with Francis Crick Institute for ALS research

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Fresh produce access boosts health outcomes among diabetes patients and those on Medicaid in recent studies

Fresh produce access boosts health outcomes among diabe...

Nov 15, 2023

Bristol Myers Squibb’s Abecma recommended for EU approval

Bristol Myers Squibb’s Abecma recommended for EU approval

Jan 29, 2024

Opinion: Listen: Cancer drug shortages should be causing more outrage

Opinion: Listen: Cancer drug shortages should be causin...

Jun 28, 2023